liebertpub.com/doi/full/10....
This cohort of antithyroid-drug–treated adult Graves’ disease patients is one of the largest reported in the literature and has one of the longest follow-up periods. The article presents new information regarding patterns of disappearance of serum TRAb concentrations over time, which appear to have an impact on the probability of remission.
The aim of the current study was to describe long-term outcomes in 549 adult patients with Graves’ disease treated with antithyroid drugs for >8 years and to relate remission and final outcomes to patterns of serum TRAb titers (6).
In the second scenario, antithyroid drugs are given for as long as necessary, until TRAbs disappear. This could be for years or even for a lifetime (4,5).
The patients were followed from 8 to 36 years. Greater than 90% of patients were treated with methimazole.
The patients were classified into four groups after follow-up: Group A0 were TRAb-negative at the outset,
Group A2 became TRAb-negative within 2 years of methimazole treatment,
Group A5 became TRAb-negative after 2 to 5 years of treatment (all combined into Group A), and
Group B, in whom TRAbs remained positive after >5 years of continuous treatment.
However, in approximately 50% of Group A patients whose TRAb became negative, TRAb levels subsequently became positive again (Group 1A); in these patients (n = 226), whose TRAb course was called “fluctuating,” the rates of remission at the end of follow-up were significantly lower than in the group whose TRAb levels remained normal (37.2% vs. 88.9%, P<0.0001).
Overall, the time to remission for all groups combined was a median of 6.8 years (interquartile range, 4.0–10.9).
The cumulative fraction going into remission was 18.2% after 5 years, 38.3% after 10 years, 41.8% after 15 years, and 52.1% after 20 years.
Approximately 6% of patients became spontaneously hypothyroid over the >8-year follow up period.
However, there were factors during antithyroid drug therapy that were predictive of failure to remit, including time to normalization of TRAb and persistence of a palpable goiter.
Conclusions
In patients with Graves’ disease, remissions often occur after 4 to 11 years of antithyroid drug therapy.
Some patients have resolution of TRAb within 2 to 5 years, while in others, TRAb levels fluctuate or remain positive for extended periods (>5 years). In this cohort, the odds of remission could not be predicted by baseline clinical or laboratory variables.
In patients hoping to avoid ablative therapy, continuous antithyroid drug therapy for >5 years is reasonable ... in patients with well-controlled mild disease (2,3).
Commentary
The 2016 American Thyroid Association clinical practice guidelines for the management of hyperthyroidism state that after 12 to 18 months of antithyroid drug therapy: “Patients with persistently high TRAb could continue ATD therapy… or opt for alternate definitive therapy with RAI or surgery.
In selected patients (i.e., younger patients with mild stable disease on a low dose of MMI), long-term MMI is a reasonable alternative approach” (2).
The present article confirms data from other series of adult (5) and pediatric (11) patients that show that remissions in Graves’ disease patients continue to be achieved after many years (>5–10) of continuous antithyroid drug therapy. Therefore, in patients who wish to avoid permanent hypothyroidism or potential complications of ablative therapy, long-term antithyroid drug therapy is a viable option.
However, in older patients (e.g., those >60 years of age), definitive therapy should be more strongly considered at the time of initial diagnosis or if TRAb titers persist for more than 1 to 2 years of antithyroid drug therapy (3).
This is because the effects of persistent or recurrent hyperthyroidism that could develop are potentially life-threatening (e.g., atrial fibrillation or other adverse cardiovascular outcome (12)) or clinically significant (e.g., osteoporosis).
While it is true that older patients are more likely to achieve remission (7), the worry that remissions are not necessarily lifelong makes definitive treatment more reasonable (3).
However, in young and middle-aged patients, long-term therapy with methimazole may become a more widely accepted strategy, especially given recent data on the adverse effects of radioiodine therapy on quality of life (13).
Failure to attain normal TRAb levels after 12 to 18 months of methimazole therapy does not rule out the possibility of remission occurring over a longer time horizon of 5 to 10 years. Even in patients with “smoldering” TRAb, about 20% became negative over prolonged follow-up.
(Please refer to the link for the full article)
Study: ‘Breakthrough’ Drug Reduces Graves’ Eye Disease Symptoms
